Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

Completed · Phase 4 · Has a placebo group

Conditions studied: Glaucoma

In brief

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

Key facts

Study ID

NCT00763061

Run by

Alcon Research

People needed

111

Starts

2006-05-01

Expected to finish

2008-04-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years;
• IOP=16-30mmHg
• OH or OAG with visual filed abnormality:
• ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p <5% on the prepapillary diameter plot, one of which must have p <1%,
• Glaucoma Hemifield Test outside normal limits,
• Corrected Pattern Standard Deviation with p <5%

You may not qualify if…

• Previous damage of anterior chamber angle;
• ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) <1.0;
• contact lens wearer;
• severe central field loss;
• uncontrolled cardiovascular, hepatic or renal disease;
• any medication within past 1 month.

Where it is running

• Alcon Call Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.